CNS Pharmaceuticals Inc. CNSP Archives - Page 2 of 22

TuesdayJul 30, 2024 10:31 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Inks Exclusive License in ‘Transformational’ Step to Treating GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into an exclusive license agreement with Cortice Biosciences Inc. Through the agreement, CNS Pharmaceuticals has acquired a license as well as the intellectual property rights to a potentially blood-brain-barrier, permeable microtubule inhibitor called TPI 287. The inhibitor is being developed for the treatment of glioblastoma multiforme (“GBM”). In return for the license, CNS Pharmaceuticals will pay Cortice an up-front payment of 616,698 shares of its common stock, as well as the possibility…

FridayJul 05, 2024 2:54 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Securities Purchase Agreements Worth Estimated $1.98M

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements, which are for the purchase and sale of 1,425,000 shares of common stock, are comprised of a registered direct offering and warrants. The offering and warrants are to purchase up to 1,425,000 shares of common stock in a concurrent private placement at a combined purchase price of $1.39 per share. The offering is expected to close today, subject to customary closing…

ThursdayMay 16, 2024 1:53 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q1 2024 Financial, Business Report

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting its financial and business results for the first quarter 2024, the period ended March 31, 2024. A highlight of the report was that enrollment is nearly completed in a potentially pivotal GBM study evaluating Berubicin with topline data expected in the first half of 2025. In addition, financial results showed a net loss for the quarter of approximately $3.5 million, down from an estimated $4.9 million net loss for the comparable period…

TuesdayApr 23, 2024 4:15 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced that its Chief Executive Officer John Climaco will present at the LSX World Congress 2024. Climaco is slated to present at 4:15 PM (GMT+1) on Monday, April 29, 2024, at the event taking place in London, England. In addition to the presentation, CNSP announced that its management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view…

MondayApr 22, 2024 3:31 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured on the Virtual Investor Lunch Break: The CNSP Opportunity event. During the live video webcast, which is scheduled to begin at 12 p.m. EST, CEO John Climaco will present a corporate overview. He will also discuss the company’s business outlook and opportunity. In addition, the event provides an opportunity for those participating to submit questions; Climaco will answer as many questions as possible I the time provided. A replay of the presentation will…

MondayApr 15, 2024 1:24 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently appointed Amy Mahery to its board of directors. “A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas… Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (‘GBM’) treatment, saying,…

TuesdayApr 02, 2024 1:09 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released financial results for the full year ending Dec. 31, 2023; the company also reported on corporate and clinical development achievement for the year. Highlights of the report included that Berubicin, the company’s lead program, has passed preplanned interim futility analysis milestones with a recommendation to proceed without modification into a potentially pivotal glioblastoma multiforme (“GBM”) study, and enrollment for the Berubicin study has been completed with topline data expected in first half…

MondayMar 18, 2024 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors

CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally The company believes Ms. Mahery’s guidance, insight, and vast pharma industry network will indeed be invaluable as the company advances Berubicin, its flagship drug candidate, toward completion of its global potentially pivotal clinical trial and potential regulatory approval The company recently completed the enrollment of patients in its potentially pivotal global clinical trial Ms. Mahery believes Berubicin represents an…

TuesdayJan 30, 2024 10:07 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of its public offering. According to the announcement, the “reasonable best efforts” public offering involves participation from healthcare-focused institutional investors and certain officers and directors of the company. The offering is comprised of the purchase and sale of 13,333,334 shares of common stock (or common stock equivalents in lieu thereof); the stock is offered at a purchase price of $0.30 per share. In addition, CNSP agreed to issue Series A warrants…

FridayJan 19, 2024 12:47 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has appointed a biotech veteran to its board of directors. The company announced that Amy Mahery, a highly accomplished biopharmaceutical industry executive, will join the company’s board effective upon completion of financing. With more than 20 years of experience working with large and small companies in common and rare conditions, Mahery brings impressive expertise in the commercialization and launch of drugs in varied therapeutic areas, including oncology, neurology, and immunology, to her new responsibilities.…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP